LMG Life Sciences Recognizes Four Marshall, Gerstein & Borun LLP Partners as Life Sciences Stars
Marshall, Gerstein & Borun LLP is pleased to have four partners recognized in the 2014 edition of LMG Life Sciences, a valued resource for pharmaceutical and life sciences executives seeking experienced legal counsel. Managing Partner Jeffrey Sharp and Partners Pamela Cox, David Gass, and Michael Muczynski are recognized as Life Sciences Stars for their outstanding patent work in life sciences.
Pamela Cox, chair of IP Transactions, concentrates on intellectual property transactions and the strategic use of intellectual property assets for clients ranging from multinational corporations to non-profit institutions. Her experience in-house, and as a patent attorney, provides a foundation for serving a quasi-general counsel function to unravel complex IP matters and devise agreements or other IP solutions as a seamless member of her client’s team. Intellectual Asset Management named Pamela “one of the foremost licensing experts both in the Midwest and nationally. She is a pre-eminent authority on university technology transfer and licensing acting for commercial and nonprofit clients.” She was named one of Managing IP's IP Stars – Top 250 Women in IP in 2014, which includes leading female intellectual property attorneys from across the United States that represent “the best of the best in their field.”
David Gass is a registered patent attorney who has served biotechnology companies, universities and research institutions for more than 20 years, helping develop and implement IP strategies for commercializing life-improving biotechnology inventions involving diagnostics and precision medicine, therapeutics and gene therapy, plants, and many other technologies. His practice focuses on acquisition and protection of intellectual property rights, especially patents, and he counsels clients about protection of IP rights, maximizing patent term and patent life-cycle for products, and freedom-to-operate issues relative to the IP rights of others. His experience before the USPTO includes interference, reexamination and reissue proceedings, appeals before the Patent Trial and Appeal Board, and patent term adjustment challenges. David also assists clients with international patent portfolio management and licensing, and advises counsel in foreign patent prosecution and opposition proceedings.
Michael Muczynski, chair of Chemical Sciences, advises clients on all issues relating to patent strategy and portfolio management, with particular emphasis in patent prosecution and opinions in pharmaceutical and other chemical fields. His clients benefit from his previous litigation experience involving generic pharmaceuticals, his ability to anticipate potential issues and strengthen patents through prosecution and lifecycle management. A substantial part of his practice involves counseling clients on strategic decisions for patenting of inventions relating to pharmaceutical products in view of FDA regulations, related exclusivity provisions, and the competitive landscape.
Jeffrey Sharp is the Managing Partner of the firm. He is a registered patent attorney with more than 30 years of experience in patent prosecution, litigation and transactional work and focuses his practice in the areas of biotechnology, chemistry and chemical engineering. Jeffrey has handled matters in a wide variety of biotechnology disciplines, such as pharmaceuticals, nutraceuticals and gene therapy; recombinant nucleic acid technologies, including plant biotechnology; and in-vivo and in-vitro diagnostic and gene-sequencing methods. He has also gained successful outcomes in diverse chemical and chemical engineering technologies, including organic, inorganic and metallurgical chemistry; chemical and metallurgical processing; and food and beverage chemistry. Beyond his extensive prosecution, counseling and opinion experience in these technologies, he has participated in numerous inter partes patent matters including patent infringement litigation before U.S. District Courts, patent interference proceedings before the U.S. Patent and Trademark Office and patent opposition work before foreign patent offices.